Base de dados : MEDLINE
Pesquisa : D03.633.300.046.250.225 [Categoria DeCS]
Referências encontradas : 1147 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 115 ir para página                         

  1 / 1147 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27998679
[Au] Autor:Infante Lara L; Sledge A; Laradji A; Okoro CO; Osheroff N
[Ad] Endereço:Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
[Ti] Título:Novel trifluoromethylated 9-amino-3,4-dihydroacridin-1(2H)-ones act as covalent poisons of human topoisomerase IIα.
[So] Source:Bioorg Med Chem Lett;27(3):586-589, 2017 02 01.
[Is] ISSN:1464-3405
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:A number of topoisomerase II-targeted anticancer drugs, including amsacrine, utilize an acridine or related aromatic core as a scaffold. Therefore, to further explore the potential of acridine-related compounds to act as topoisomerase II poisons, we synthesized a series of novel trifluoromethylated 9-amino-3,4-dihydroacridin-1(2H)-one derivatives and examined their ability to enhance DNA cleavage mediated by human topoisomerase IIα. Derivatives containing a H, Cl, F, and Br at C7 enhanced enzyme-mediated double-stranded DNA cleavage ∼5.5- to 8.5-fold over baseline, but were less potent than amsacrine. The inclusion of an amino group at C9 was critical for activity. The compounds lost their activity against topoisomerase IIα in the presence of a reducing agent, displayed no activity against the catalytic core of topoisomerase IIα, and inhibited DNA cleavage when incubated with the enzyme prior to the addition of DNA. These findings strongly suggest that the compounds act as covalent, rather than interfacial, topoisomerase II poisons.
[Mh] Termos MeSH primário: Acridinas/química
Acridinas/farmacologia
Antígenos de Neoplasias/metabolismo
DNA Topoisomerases Tipo II/metabolismo
Proteínas de Ligação a DNA/metabolismo
[Mh] Termos MeSH secundário: Amsacrina/química
Antineoplásicos/química
Antineoplásicos/farmacologia
DNA/metabolismo
Clivagem do DNA/efeitos dos fármacos
Ativação Enzimática/efeitos dos fármacos
Seres Humanos
Substâncias Intercalantes/química
Inibidores da Topoisomerase II/química
Inibidores da Topoisomerase II/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Acridines); 0 (Antigens, Neoplasm); 0 (Antineoplastic Agents); 0 (DNA-Binding Proteins); 0 (Intercalating Agents); 0 (Topoisomerase II Inhibitors); 00DPD30SOY (Amsacrine); 9007-49-2 (DNA); EC 5.99.1.3 (DNA Topoisomerases, Type II)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:171124
[Lr] Data última revisão:
171124
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161222
[St] Status:MEDLINE


  2 / 1147 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27064820
[Au] Autor:Bhowmik D; Suresh Kumar G
[Ad] Endereço:a Biophysical Chemistry Laboratory , CSIR-Indian Institute of Chemical Biology , Kolkata 700 032 , India.
[Ti] Título:A comparative spectroscopic and calorimetric investigation of the interaction of amsacrine with heme proteins, hemoglobin and myoglobin.
[So] Source:J Biomol Struct Dyn;35(6):1260-1271, 2017 May.
[Is] ISSN:1538-0254
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The binding of the anilido aminoacridine derivative amsacrine with the heme proteins, hemoglobin, and myoglobin, was characterized by various spectroscopic and calorimetric methods. The binding affinity to hemoglobin was (1.21 ± .05) × 10 M , while that to myoglobin was three times higher (3.59 ± .15) × 10 M . The temperature-dependent fluorescence study confirmed the formation of ground-state complexes with both the proteins. The stronger binding to myoglobin was confirmed from both spectroscopic and calorimetric studies. The binding was exothermic in both cases at the three temperatures studied, and was favored by both enthalpy and entropy changes. Circular dichroism results, three-dimensional (3D) and synchronous fluorescence studies confirmed that the binding of amsacrine significantly changed the secondary structure of hemoglobin, while the change in the secondary structure of myoglobin was much less. New insights, in terms of structural and energetic aspects of the interaction of amsacrine with the heme proteins, presented here may help in understanding the structure-activity relationship, therapeutic efficacy, and drug design aspects of acridines.
[Mh] Termos MeSH primário: Amsacrina/química
Calorimetria
Hemoglobinas/química
Mioglobina/química
Análise Espectral
[Mh] Termos MeSH secundário: Amsacrina/metabolismo
Calorimetria/métodos
Hemoglobinas/metabolismo
Seres Humanos
Ligantes
Estrutura Molecular
Mioglobina/metabolismo
Ligação Proteica
Análise Espectral/métodos
Termodinâmica
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hemoglobins); 0 (Ligands); 0 (Myoglobin); 00DPD30SOY (Amsacrine)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170531
[Lr] Data última revisão:
170531
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160412
[St] Status:MEDLINE
[do] DOI:10.1080/07391102.2016.1176958


  3 / 1147 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27321375
[Au] Autor:Afzal A; Sarfraz M; Wu Z; Wang G; Sun J
[Ad] Endereço:Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University (CPU), Nanjing, China. Electronic address: attiapharm@gmail.com.
[Ti] Título:Integrated scientific data bases review on asulacrine and associated toxicity.
[So] Source:Crit Rev Oncol Hematol;104:78-86, 2016 Aug.
[Is] ISSN:1879-0461
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Asulacrine (ASL), a weakly basic and highly lipophilic drug was synthesized in 1980's in cancer research laboratory of Auckland by modifications to the acridine portion of amsacrine on 3-, 4- and 5-substitution patterns. In contrast to its precursor amsacrine (m-AMSA), ASL was effective not only against leukemia and Lewis lung tumor system but also a wide variety of solid tumor. Its metabolic pathway is not same to amsacrine hence different side effects, hepatotoxicity and excretion was observed. Asulacrine is under phase II clinical trials and has showed promising results but its toxicity especially phlebitis is stumbling block in its clinical implementation. This review is an effort to give a possible clue, based on scientifically proven results, to the researchers to solve the mystery of associated toxicity, phlebitis. Review covers the available literature on asulacrine and other acridine derivatives regarding pharmacology, pharmacokinetics, quantitative structure activity relationship and toxicology via electronic search using scientific databases like PubMed and others. To date, all abstracts and full-text articles were discussed and analyzed. The tabulated comparisons and circuitry mechanism of ASL are the added features of the review which give a complete understanding of hidden aspects of possible route cause of associated toxicity, the phlebitis.
[Mh] Termos MeSH primário: Amsacrina/análogos & derivados
Antineoplásicos/efeitos adversos
Neoplasias/tratamento farmacológico
[Mh] Termos MeSH secundário: Amsacrina/efeitos adversos
Amsacrina/uso terapêutico
Animais
Antineoplásicos/uso terapêutico
Seres Humanos
Estresse Oxidativo/efeitos dos fármacos
Transdução de Sinais/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antineoplastic Agents); 00DPD30SOY (Amsacrine); S8P50T62B6 (asulacrine)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170113
[Lr] Data última revisão:
170113
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160621
[St] Status:MEDLINE


  4 / 1147 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27187844
[Au] Autor:Zang X; Zhang J; Zhou Y; Chen Q; Peng Y; Sun J; Liu J; Liu W; Wang G; Zhou F
[Ad] Endereço:Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.
[Ti] Título:Quantitative determination of intracellular Asulacrine in MCF-7 breast cancer cells by liquid chromatography-mass spectrometry and its application to cellular pharmacokinetic studies of P188 modified liposomes.
[So] Source:Biomed Chromatogr;30(12):1908-1914, 2016 Dec.
[Is] ISSN:1099-0801
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Asulacrine (ASL), an analogue of amsacrine, has shown higher anti-breast and anti-lung cancer activity. Hereby, a new sensitive and selective liquid chromatography-mass spectrometry (LC/MS) method was developed to determine intracellular asulacrine. The chromatographic separation was performed on an Agilent Zorbax Extend-C column (2.1 mm i.d. × 50 mm, 5 µm) using gradient elution with water (2 mmol/L ammonium acetate and 0.1% acetic acid) and acetonitrile as the mobile phase. The detection was achieved with selected ion monitoring mode using electrospray ionization in positive mode with target ions at m/z 465.3 and m/z 326.1 for asulacrine and midazolam, respectively. The standard curve showed a good linearity with the lower limit of quantification of 1 ng/mL, as a result of which, the trace concentration of ASL in cell suspension could be quantified. The intra- and inter-day accuracy ranged from -5.28 to 6.5% and from -6.32 to 1.05%, and the intra- and inter-day precisions were no more than 7.65% and 11.71%, respectively. Additionally, no degradation of asulacrine was observed during stability evaluation. The method was proved to be powerful and practical to determine and compare the intracellular distribution and kinetics of ASL under different formulations in MCF-7 breast cancer cells.
[Mh] Termos MeSH primário: Amsacrina/análogos & derivados
Antineoplásicos/farmacocinética
Neoplasias da Mama/metabolismo
Cromatografia Líquida/métodos
Lipossomos
Espectrometria de Massas/métodos
[Mh] Termos MeSH secundário: Amsacrina/farmacocinética
Neoplasias da Mama/patologia
Feminino
Seres Humanos
Células MCF-7
Reprodutibilidade dos Testes
[Pt] Tipo de publicação:JOURNAL ARTICLE; VALIDATION STUDIES
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Liposomes); 00DPD30SOY (Amsacrine); S8P50T62B6 (asulacrine)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170208
[Lr] Data última revisão:
170208
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160518
[St] Status:MEDLINE
[do] DOI:10.1002/bmc.3762


  5 / 1147 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27060564
[Au] Autor:Coelho J; Ferreira F; Martins C; Leitão A
[Ad] Endereço:CIISA, Faculdade de Medicina Veterinária, ULisboa, Avenida da Universidade Técnica, 1300-477 Lisboa, Portugal. Electronic address: jnscoelho@gmail.com.
[Ti] Título:Functional characterization and inhibition of the type II DNA topoisomerase coded by African swine fever virus.
[So] Source:Virology;493:209-16, 2016 Jun.
[Is] ISSN:1096-0341
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:DNA topoisomerases are essential for DNA metabolism and while their role is well studied in prokaryotes and eukaryotes, it is less known for virally-encoded topoisomerases. African swine fever virus (ASFV) is a nucleo-cytoplasmic large DNA virus that infects Ornithodoros ticks and all members of the family Suidae, representing a global threat for pig husbandry with no effective vaccine nor treatment. It was recently demonstrated that ASFV codes for a type II topoisomerase, highlighting a possible target for control of the virus. In this work, the ASFV DNA topoisomerase II was expressed in Saccharomyces cerevisiae and found to efficiently decatenate kDNA and to processively relax supercoiled DNA. Optimal conditions for its activity were determined and its sensitivity to a panel of topoisomerase poisons and inhibitors was evaluated. Overall, our results provide new knowledge on viral topoisomerases and on ASFV, as well as a possible target for the control of this virus.
[Mh] Termos MeSH primário: Vírus da Febre Suína Africana/enzimologia
DNA Topoisomerases Tipo II/genética
Inibidores da Topoisomerase II/farmacologia
[Mh] Termos MeSH secundário: Vírus da Febre Suína Africana/genética
Aminocumarinas/farmacologia
Amsacrina/farmacologia
Crithidia fasciculata/genética
Doxorrubicina/farmacologia
Saccharomyces cerevisiae/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Aminocoumarins); 0 (Topoisomerase II Inhibitors); 00DPD30SOY (Amsacrine); 80168379AG (Doxorubicin); EC 5.99.1.3 (DNA Topoisomerases, Type II); PCH9QZ1IIH (coumermycin)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170509
[Lr] Data última revisão:
170509
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160410
[St] Status:MEDLINE


  6 / 1147 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27040513
[Au] Autor:Afzal A; Zhong Y; Sarfraz M; Peng Y; Sheng L; Wu Z; Sun J; Wang G
[Ad] Endereço:Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University (CPU), Nanjing, China.
[Ti] Título:Identification and characterization of in vivo metabolites of asulacrine using advanced mass spectrophotometry technique in combination with improved data mining strategy.
[So] Source:J Chromatogr A;1444:74-85, 2016 Apr 29.
[Is] ISSN:1873-3778
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Asulacrine (ASL) is a broad-spectrum, antitumor drug whose data are promising for the treatment of breast and lung cancers; however, a high incidence of phlebitis hampered its further development. Phlebitis is associated with generation of reactive species. Asulacrine donates electrons and produces oxidative stress in chemical reactions. It was expected that ASL would actively metabolize to oxidized products through reactive intermediates and produce more products in vivo than reported and thus cause phlebitis. A comprehensive study was planned to investigate in vivo metabolism of ASL, using high-resolution mass spectrometry LC/IT-TOF MS in positive mode. Metabolites were detected by different software by applying annotated detection strategy. The possible metabolites and their product ions were simultaneously detected by segmented data acquisition to get accurate mass values. Segmented data acquisition improved signal-to-noise (S/N) ratio, which was helpful to detect metabolites and their fragments even when present in trace amounts. A total of 21 metabolites were detected in gender-based biological fluids and characterized by comparing their accurate mass values, fragmentation patterns, and relative retention times with that of ASL. Among previously reported glucuronosylation metabolites, some oxidation, hydroxylation, carboxylation, demethylation, hydrogenation, glutamination, and acetylcysteine conjugation were detected for the first time. Twenty metabolites were tentatively identified by using the annotated strategy for data acquisition and post-data mining.
[Mh] Termos MeSH primário: Amsacrina/análogos & derivados
Mineração de Dados
Espectrometria de Massas
[Mh] Termos MeSH secundário: Amsacrina/metabolismo
Animais
Bile/química
Feminino
Masculino
Peso Molecular
Ratos
Software
Urina/química
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
00DPD30SOY (Amsacrine); S8P50T62B6 (asulacrine)
[Em] Mês de entrada:1609
[Cu] Atualização por classe:161126
[Lr] Data última revisão:
161126
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160405
[St] Status:MEDLINE


  7 / 1147 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27021465
[Au] Autor:Zhang W; Falconer JR; Baguley BC; Shaw JP; Kanamala M; Xu H; Wang G; Liu J; Wu Z
[Ad] Endereço:School of Pharmacy, The University of Auckland, Auckland 1142, New Zealand; China Pharmaceutical University, Nanjing 210009, PR China.
[Ti] Título:Improving drug retention in liposomes by aging with the aid of glucose.
[So] Source:Int J Pharm;505(1-2):194-203, 2016 May 30.
[Is] ISSN:1873-3476
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:This paper describes a novel method to improve drug retention in liposomes for the poorly water-soluble (lipophilic) model drug asulacrine (ASL). ASL was loaded in the aqueous phase of liposomes and the effects of aging conditions and drug loading levels on drug retention were investigated using an in vitro bio-relevant drug release test established in this study. The status of intra-liposomal drug was investigated using differential scanning calorimetry (DSC) and cryo-transmission electron microscopy (cryo-TEM). Pharmacokinetics and venous tolerance of the formulations were simultaneously studied in rabbits following one-hour intravenous infusion via the ear vein. The presence of glucose during aging was found to be crucial to accelerate drug precipitation and to stabilize the liposomal membrane with high drug loading (8.9% over 4.5% w/w) as a prerequisite. Although no drug crystals were detected, DSC showed a lower phase-transition peak in the glucose-assisted aged ASL-liposomes, indicating interaction of phospholipids with the sugar. Cryo-TEM revealed more 'coffee bean' like drug precipitate in the ASL-liposomes aged in the glucose solution. In rabbits, these liposomes gave rise to a 1.9 times longer half-life than the fresh liposomes, with no venous irritation observed. Inducing and stabilizing drug precipitation in the liposome cores by aging in the presence of sugar provided an easy approach to improve drug retention in liposomes. The study also highlighted the importance of bio-relevance of in vitro release methods to predict in vivo drug release.
[Mh] Termos MeSH primário: Amsacrina/análogos & derivados
Antineoplásicos/administração & dosagem
Glucose/química
[Mh] Termos MeSH secundário: Amsacrina/administração & dosagem
Amsacrina/química
Animais
Antineoplásicos/química
Varredura Diferencial de Calorimetria
Precipitação Química
Química Farmacêutica/métodos
Liberação Controlada de Fármacos
Meia-Vida
Infusões Intravenosas
Lipossomos
Microscopia Eletrônica de Transmissão
Transição de Fase
Coelhos
Solubilidade
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Liposomes); 00DPD30SOY (Amsacrine); IY9XDZ35W2 (Glucose); S8P50T62B6 (asulacrine)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170410
[Lr] Data última revisão:
170410
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160330
[St] Status:MEDLINE


  8 / 1147 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:27019595
[Au] Autor:Fang YP; Chuang CH; Wu PC; Huang YB; Tzeng CC; Chen YL; Liu YT; Tsai YH; Tsai MJ
[Ad] Endereço:School of Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan.
[Ti] Título:Amsacrine analog-loaded solid lipid nanoparticle to resolve insolubility for injection delivery: characterization and pharmacokinetics.
[So] Source:Drug Des Devel Ther;10:1019-28, 2016.
[Is] ISSN:1177-8881
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:Amsacrine analog is a novel chemotherapeutic agent that provides potentially broad antitumor activity when compared to traditional amsacrine. However, the major limitation of amsacrine analog is that it is highly lipophilic, making it nonconductive to intravenous administration. The aim of this study was to utilize solid lipid nanoparticles (SLN) to resolve the delivery problem and to investigate the biodistribution of amsacrine analog-loaded SLN. Physicochemical characterizations of SLN, including particle size, zeta potential, entrapment efficiency, and stability, were evaluated. In vitro release behavior was also measured by the dialysis method. In vivo pharmacokinetics and biodistribution behavior of amsacrine analog were investigated and incorporated with a non invasion in vivo imaging system to confirm the localization of SLN. The results showed that amsacrine analog-loaded SLN was 36.7 nm in particle size, 0.37 in polydispersity index, and 34.5±0.047 mV in zeta potential. More than 99% of amsacrine analog was successfully entrapped in the SLN. There were no significant differences in the physicochemical properties after storage at room temperature (25°C) for 1 month. Amsacrine analog-loaded SLN maintained good stability. An in vitro release study showed that amsacrine analog-loaded SLN sustained a release pattern and followed the zero equation. An in vivo pharmacokinetics study showed that amsacrine analog was rapidly distributed from the central compartment to the tissue compartments after intravenous delivery of amsacrine analog-loaded SLN. The biodistribution behavior demonstrated that amsacrine analog mainly accumulated in the lungs. Noninvasion in vivo imaging system images also confirmed that the drug distribution was predominantly localized in the lungs when IR-780-loaded SLN was used.
[Mh] Termos MeSH primário: Amsacrina/análogos & derivados
Amsacrina/farmacocinética
Sistemas de Liberação de Medicamentos
Lipídeos/química
Nanopartículas/administração & dosagem
Nanopartículas/química
[Mh] Termos MeSH secundário: Amsacrina/administração & dosagem
Amsacrina/sangue
Animais
Cromatografia Líquida de Alta Pressão
Injeções Intraperitoneais
Camundongos
Camundongos Endogâmicos ICR
Estrutura Molecular
Tamanho da Partícula
Solubilidade
Propriedades de Superfície
Distribuição Tecidual
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Lipids); 00DPD30SOY (Amsacrine)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160329
[St] Status:MEDLINE
[do] DOI:10.2147/DDDT.S97161


  9 / 1147 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27002947
[Au] Autor:DeVita VT; Canellos GP
[Ad] Endereço:Yale Cancer Center, Yale University School of Medicine, New Haven, CT - USA.
[Ti] Título:Combination chemotherapy of solid tumors: an American-Italian collaboration: a celebration of the work of Gianni Bonadonna.
[So] Source:Tumori;102(2):124-6, 2016 Mar-Apr.
[Is] ISSN:2038-2529
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:This article highlights the important collaboration between the U.S. NCI in Bethesda, Maryland and the Istituto Tumori in Milan, Italy that had a major impact on the development of curative regimens for breast cancer, Hodgkin's disease and diffuse large B cell lymphoma.In addition to his contribution to developing new therapies, Gianni Bonadonna played an important role in bringing highly focused, disciplined, ethical clinical trials to the European continent.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Neoplasias da Mama/tratamento farmacológico
Doença de Hodgkin/tratamento farmacológico
Linfoma não Hodgkin/tratamento farmacológico
Oncologia/história
[Mh] Termos MeSH secundário: Amsacrina/administração & dosagem
Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem
Protocolos de Quimioterapia Combinada Antineoplásica/história
Bleomicina/administração & dosagem
Neoplasias da Mama/história
Neoplasias da Mama/mortalidade
Ensaios Clínicos como Assunto/história
Comportamento Cooperativo
Ciclofosfamida/administração & dosagem
Ciclofosfamida/história
Doxorrubicina/administração & dosagem
Esquema de Medicação
Feminino
Fluoruracila/administração & dosagem
Fluoruracila/história
História do Século XX
História do Século XXI
Doença de Hodgkin/história
Doença de Hodgkin/mortalidade
Seres Humanos
Itália
Tábuas de Vida
Linfoma não Hodgkin/história
Linfoma não Hodgkin/mortalidade
Masculino
Mecloretamina/administração & dosagem
Mecloretamina/história
Metotrexato/administração & dosagem
Metotrexato/história
National Cancer Institute (U.S.)
Prednisona/administração & dosagem
Prednisona/história
Procarbazina/administração & dosagem
Procarbazina/história
Estados Unidos
Vincristina/administração & dosagem
Vincristina/história
[Pt] Tipo de publicação:BIOGRAPHY; HISTORICAL ARTICLE; JOURNAL ARTICLE; REVIEW
[Ps] Nome de pessoa como assunto:Bonadonna G
[Nm] Nome de substância:
00DPD30SOY (Amsacrine); 11056-06-7 (Bleomycin); 35S93Y190K (Procarbazine); 50D9XSG0VR (Mechlorethamine); 5J49Q6B70F (Vincristine); 80168379AG (Doxorubicin); 8N3DW7272P (Cyclophosphamide); U3P01618RT (Fluorouracil); VB0R961HZT (Prednisone); YL5FZ2Y5U1 (Methotrexate)
[Em] Mês de entrada:1609
[Cu] Atualização por classe:160420
[Lr] Data última revisão:
160420
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160323
[St] Status:MEDLINE
[do] DOI:10.5301/tj.5000492


  10 / 1147 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26678609
[Au] Autor:Hayes F
[Ad] Endereço:Faculty of Life Sciences, The University of Manchester, Manchester, UK.
[Ti] Título:Probe discovery: Disentangling gene networks.
[So] Source:Nat Chem Biol;12(1):3-4, 2016 Jan.
[Is] ISSN:1552-4469
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Amsacrina/farmacologia
Antibacterianos/farmacologia
Proteínas de Bactérias/antagonistas & inibidores
Avaliação Pré-Clínica de Medicamentos/métodos
Staphylococcus aureus/efeitos dos fármacos
[Pt] Tipo de publicação:COMMENT; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Bacterial Proteins); 00DPD30SOY (Amsacrine)
[Em] Mês de entrada:1604
[Cu] Atualização por classe:170922
[Lr] Data última revisão:
170922
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151219
[St] Status:MEDLINE
[do] DOI:10.1038/nchembio.1983



página 1 de 115 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde